{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":7,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06467357\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DESTINY-BTC01","nct_id":"NCT06467357","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-btc01-nct06467357. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"DESTINY-BTC01","arms":[{"description":"Trastuzumab deruxtecan (T-DXd; DS-8201a) in combination with rilvegostomig arm","label":"Trastuzumab deruxtecan + rilvegostomig","type":"EXPERIMENTAL"},{"description":"Trastuzumab deruxtecan (T-DXd; DS-8201a) arm","label":"Trastuzumab deruxtecan","type":"EXPERIMENTAL"},{"description":"Gemcitabine and cisplatin in combination with durvalumab arm","label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-05-16","type":"ESTIMATED"},"conditions":["Biliary Tract Cancer"],"enrollment":{"count":620,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Gemcitabine","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Durvalumab","type":"DRUG"},{"name":"Trastuzumab deruxtecan","type":"DRUG"},{"name":"Rilvegostomig","type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"AstraZeneca","official_title":"DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety Run In: To evaluate the safety and tolerability of T-DXd with rilvegostomig","timeFrame":"Until all patients have completed at least 1 full Cycle (each cycle is 21 days)"},{"measure":"Randomized Portion: To evaluate the efficacy of T-DXd with rilvegostomig vs Standard of Care (SoC) in terms of Overall Survival in the FAS (HER2 IHC 3+) population","timeFrame":"From date of treatment randomization until the date of death from any cause (estimated to be assessed up to 50 months after first subject randomized)"}],"references":[],"start_date":{"date":"2024-08-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","url":"https://clinicaltrials.gov/study/NCT06467357"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-btc01-nct06467357"}